7JVN

Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor Compound 24


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.92 Å
  • R-Value Free: 0.214 
  • R-Value Work: 0.181 
  • R-Value Observed: 0.183 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.1 of the entry. See complete history


Literature

Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer.

LaMarche, M.J.Acker, M.Argintaru, A.Bauer, D.Boisclair, J.Chan, H.Chen, C.H.Chen, Y.N.Chen, Z.Deng, Z.Dore, M.Dunstan, D.Fan, J.Fekkes, P.Firestone, B.Fodor, M.Garcia-Fortanet, J.Fortin, P.D.Fridrich, C.Giraldes, J.Glick, M.Grunenfelder, D.Hao, H.X.Hentemann, M.Ho, S.Jouk, A.Kang, Z.B.Karki, R.Kato, M.Keen, N.Koenig, R.LaBonte, L.R.Larrow, J.Liu, G.Liu, S.Majumdar, D.Mathieu, S.Meyer, M.J.Mohseni, M.Ntaganda, R.Palermo, M.Perez, L.Pu, M.Ramsey, T.Reilly, J.Sarver, P.Sellers, W.R.Sendzik, M.Shultz, M.D.Slisz, J.Slocum, K.Smith, T.Spence, S.Stams, T.Straub, C.Tamez Jr., V.Toure, B.B.Towler, C.Wang, P.Wang, H.Williams, S.L.Yang, F.Yu, B.Zhang, J.H.Zhu, S.

(2020) J Med Chem 63: 13578-13594

  • DOI: 10.1021/acs.jmedchem.0c01170
  • Primary Citation of Related Structures:  
    7JVM, 7JVN

  • PubMed Abstract: 
  • SHP2 is a nonreceptor protein tyrosine phosphatase encoded by the PTPN11 gene and is involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also plays an important role in the programed cell death pathway (PD-1/PD-L1). As an oncoprotein as well as a potential immunomodulator, controlling SHP2 activity is of high therapeutic interest ...

    SHP2 is a nonreceptor protein tyrosine phosphatase encoded by the PTPN11 gene and is involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also plays an important role in the programed cell death pathway (PD-1/PD-L1). As an oncoprotein as well as a potential immunomodulator, controlling SHP2 activity is of high therapeutic interest. As part of our comprehensive program targeting SHP2, we identified multiple allosteric binding modes of inhibition and optimized numerous chemical scaffolds in parallel. In this drug annotation report, we detail the identification and optimization of the pyrazine class of allosteric SHP2 inhibitors. Structure and property based drug design enabled the identification of protein-ligand interactions, potent cellular inhibition, control of physicochemical, pharmaceutical and selectivity properties, and potent in vivo antitumor activity. These studies culminated in the discovery of TNO155, (3 S ,4 S )-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine ( 1 ), a highly potent, selective, orally efficacious, and first-in-class SHP2 inhibitor currently in clinical trials for cancer.


    Organizational Affiliation

    Structural Motility, UMR 144 CNRS/Curie Institute, 26 rue d'ulm, 75258, Paris cedex 05, France. anne.houdusse@curie.fr.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Tyrosine-protein phosphatase non-receptor type 11A, B525Homo sapiensMutation(s): 0 
Gene Names: PTPN11PTP2CSHPTP2
EC: 3.1.3.48
UniProt & NIH Common Fund Data Resources
Find proteins for Q06124 (Homo sapiens)
Explore Q06124 
Go to UniProtKB:  Q06124
PHAROS:  Q06124
Protein Feature View
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.92 Å
  • R-Value Free: 0.214 
  • R-Value Work: 0.181 
  • R-Value Observed: 0.183 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 46.09α = 90
b = 214.736β = 97.09
c = 55.84γ = 90
Software Package:
Software NamePurpose
SCALAdata scaling
BUSTERrefinement
PDB_EXTRACTdata extraction
XDSdata reduction
BUSTERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment  



Entry History 

Deposition Data

  • Deposited Date: 2020-08-21 
  • Released Date: 2020-09-23 
  • Deposition Author(s): Fodor, M., Stams, T.

Revision History  (Full details and data files)

  • Version 1.0: 2020-09-23
    Type: Initial release
  • Version 1.1: 2020-12-09
    Changes: Database references